Mena FN

Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism Of Analgesic Effect In Chronic Neuropathic Pain Model And Demonstrating Statistically ...

(MENAFN- GlobeNewsWire - Nasdaq) TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 ...
Benzinga.com

What's Going On With Neurological Disease Focused Trevena On Thursday?

Shares of Trevena Inc (NASDAQ:TRVN) are trading lower on Thursday, with a session volume of 23.65 million, as per data from Benzinga Pro. The company released preclinical data from two separate ...
Investing

Trevena's SWOT analysis: CNS drug developer's stock faces pivotal moment

Trevena, Inc. (NASDAQ:OTC:TRVN), a biopharmaceutical company specializing in central nervous system (CNS) disorders, finds itself at a critical juncture as it navigates challenges and opportunities in ...
Finanznachrichten

Trevena, Inc.: Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating ...

TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, ...